BioNxt Expands Sublingual Product Pipeline with Innovations

BioNxt Solutions Inc., a bioscience company, has announced the expansion of its product pipeline. The company focuses on next-generation drug delivery systems like Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet). These systems target autoimmune diseases such as Multiple Sclerosis, Myasthenia Gravis, Lupus Nephritis, and Rheumatoid Arthritis. Additionally, BioNxt is entering the longevity market with solutions aimed at anti-aging.

Key products include BNT23001, a sublingual Cladribine for Multiple Sclerosis, and a similar approach for Myasthenia Gravis. For Lupus Nephritis, BioNxt is developing a thin-film product to increase bioavailability. Their Rheumatoid Arthritis solution uses both sublingual and oral technologies.

In the anti-aging sector, BioNxt is developing pharmaceuticals addressing aging factors to enhance health and longevity. These efforts highlight BioNxt's commitment to patient-friendly therapeutic advancements. CEO Hugh Rogers emphasizes their role in addressing unmet medical needs and fostering growth.